Matthew Milowsky, MD, FASCO (IMAGE)
Caption
“The overarching goal of our study was to provide every patient with metastatic urothelial cancer the opportunity to become an exceptional responder and to develop a rich clinical database and biorepository for future collaborative research efforts. Most significantly, these findings provide a potential way to predict response to immunotherapies by integrating clinical and molecular features,” said Matthew Milowsky, MD, FASCO, director of the Urologic Oncology Program at UNC Lineberger Comprehensive Cancer Center.
Credit
UNC Lineberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content